MANNKIND CORP Research and Development in Process
MANNKIND CORP (MNKD) reported Research and Development in Process of $13.23 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-02-23
- MANNKIND CORP research and development in process for fiscal 2020 was $13.23M.
| Period end | Research and Development in Process 0 month | Research and Development in Process 1 month | Research and Development in Process 12 month | Research and Development in Process 244 month | Research and Development in Process 247 month | Research and Development in Process 250 month | Research and Development in Process 253 month | Research and Development in Process 256 month | Research and Development in Process 259 month | Research and Development in Process 263 month | Research and Development in Process 265 month | Research and Development in Process 268 month | Research and Development in Process 271 month | Research and Development in Process 275 month | Research and Development in Process 277 month | Research and Development in Process 280 month | Research and Development in Process 283 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $13.23M 10-K · filed 2023-02-23 | ||||||||||||||||
| 2014-09-30 | $19.73M 10-Q · filed 2014-11-10 | ||||||||||||||||
| 2014-06-30 | $19.73M 10-Q · filed 2014-08-11 | ||||||||||||||||
| 2014-03-31 | $19.73M 10-Q · filed 2014-05-12 | ||||||||||||||||
| 2013-12-31 | $19.73M 10-K · filed 2014-03-03 | ||||||||||||||||
| 2013-09-30 | $19.73M 10-Q · filed 2013-11-12 | ||||||||||||||||
| 2013-06-30 | $19.73M 10-Q · filed 2013-08-09 | ||||||||||||||||
| 2013-03-31 | $19.73M 10-Q · filed 2013-05-10 | ||||||||||||||||
| 2012-12-31 | $19.73M 10-K · filed 2013-03-18 | ||||||||||||||||
| 2012-09-30 | $19.73M 10-Q · filed 2012-11-09 | ||||||||||||||||
| 2012-06-30 | $19.73M 10-Q · filed 2012-08-09 | ||||||||||||||||
| 2012-03-31 | $19.73M 10-Q · filed 2012-05-10 | ||||||||||||||||
| 2011-12-31 | $19.73M 10-K · filed 2012-03-15 | ||||||||||||||||
| 2011-09-30 | $19.73M 10-Q · filed 2011-11-04 | ||||||||||||||||
| 2011-06-30 | $19.73M 10-Q · filed 2011-08-04 | ||||||||||||||||
| 2001-12-12 | $19.70M 10-K · filed 2014-03-03 | $19.70M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |